|
Research Management and Support
|
RMS ES 2017
|
$326,124,631
|
N/A
|
National Institutes of Health
|
|
Cancer Center Support Grant
|
3P30CA013696-43S1
|
$120,000
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S2
|
$60,000
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S3
|
$118,652
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S4
|
$199,541
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
5P30CA013696-43
|
$3,792,720
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Development of personalized surgical algorithms for muscle-invasive bladder cancer patients
|
1R21CA218976-01
|
$199,013
|
ABBOSH, PHILIP
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
Quantitative MRI for Predicting Response of Breast Cancer to Neoadjuvant Therapy
|
5U01CA142565-09
|
$461,999
|
ABRAMSON, RICHARD
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
Center for Multiple Myeloma Nanotherapy
|
3U54CA199092-03S1
|
$29,864
|
ACHILEFU, SAMUEL
|
WASHINGTON UNIVERSITY
|
|
Center for Multiple Myeloma Nanotherapy
|
5U54CA199092-03
|
$2,224,884
|
ACHILEFU, SAMUEL
|
WASHINGTON UNIVERSITY
|
|
Identifying the Drivers and Targeting Chemo Resistance in Ovarian Cancer
|
1R01CA211648-01A1
|
$429,211
|
ADLI, MAZHAR
|
UNIVERSITY OF VIRGINIA
|
|
Plumbagin in Combination with Vemurafenib for BRAF-mutant Melanoma
|
1R03CA212798-01
|
$74,250
|
AFAQ, FARRUKH
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Novel Combinatorial Therapeutic Approach for Prostate Cancer
|
1R03CA219336-01
|
$74,250
|
AFAQ, FARRUKH
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Skin Cancer Chemoprevention by Silibinin: Mechanisms and Efficacy
|
2R01CA140368-06
|
$369,313
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
CCNY-MSKCC Partnership for Cancer Research Training & Community Outreach (1 of 2
|
5U54CA137788-10
|
$1,469,019
|
AHLES, TIM
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Inhibition of Hedgehog Signaling in Gli-1+Adeno CA of the Esoph or GE junction
|
5R01CA172741-05
|
$279,793
|
AJANI, JAFFER
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Use of Genetically Engineered T cells Targeting Tumor Stroma to Treat Lung Cancer
|
5R01CA172921-05
|
$357,673
|
ALBELDA, STEVEN
|
UNIVERSITY OF PENNSYLVANIA
|
|
Targeting Tumor Initiating Cell in Undifferentiated Pleomorphic Sarcoma
|
5R01CA183811-04
|
$435,560
|
ALMAN, BENJAMIN
|
DUKE UNIVERSITY
|
|
Therapeutic resistance in leukemic cells: targeting BCL-2 family and autophagy
|
5R01CA184137-03
|
$362,569
|
ALMASAN, ALEXANDRU
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Multi-Tensor Decompositions for Personalized Cancer Diagnostics and Prognostics
|
5U01CA202144-03
|
$704,509
|
ALTER, ORLY
|
UNIVERSITY OF UTAH
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-48S1
|
$142,498
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
5P30CA010815-48
|
$2,645,581
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Novel Markers for Disease Outcome in Breast Cancer
|
ZIA BC 010887
|
$519,415
|
Ambs, Stefan
|
CCR (NCI)
|
|
The development of radiolabeled probes for imaging and therapy which target the chemokine CXCR4
|
5F32CA203473-02
|
$59,166
|
AMOR-COARASA, ALEJANDRO
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
Novel Dual Notch/PXR Targeting for Colon Cancer Therapy
|
5R01CA182872-04
|
$688,666
|
ANANT, SHRIKANT
|
UNIVERSITY OF KANSAS MEDICAL CENTER
|
|
Sensitization to CD47 Blockade to Enhance Anti-Tumor Immunity
|
5F30CA195973-03
|
$42,914
|
ANDERSON, KATIE
|
UNIVERSITY OF MINNESOTA
|
|
SPORE in Multple Myeloma
|
5P50CA100707-15
|
$2,300,000
|
ANDERSON, KENNETH
|
DANA-FARBER CANCER INST
|
|
Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications
|
5R01CA050947-25
|
$301,545
|
ANDERSON, KENNETH
|
DANA-FARBER CANCER INST
|
|
Clinical trials in women's cancers
|
ZIA BC 011584
|
$206,100
|
Annunziata, Christina
|
CCR (NCI)
|
|
Targeting the MET pathway in urothelial carcinoma
|
ZIA BC 011594
|
$536,543
|
Apolo, Andrea
|
CCR (NCI)
|
|
Childhood Cancer Survivor Study
|
2U24CA055727-23
|
$3,616,741
|
ARMSTRONG, GREGORY
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Cancer Center Support Grant - UT Southwestern Medical Center
|
3P30CA142543-08S1
|
$175,000
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Cancer Center Support Grant - UT Southwestern Medical Center
|
5P30CA142543-08
|
$2,480,000
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Cancer Center Support Grant
|
3P30CA082103-18S9
|
$6,765,398
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-18SA
|
$124,999
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-18SB
|
$59,999
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
A Prospective Study of the Impact of Breast Cancer on Symptoms and Functioning
|
5R01CA199137-03
|
$392,439
|
AVIS, NANCY
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
|
UW Comprehensive Cancer Center Support
|
3P30CA014520-43S1
|
$125,000
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UW Comprehensive Cancer Center Support
|
3P30CA014520-43S2
|
$31,772
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UW Comprehensive Cancer Center Support
|
5P30CA014520-43
|
$4,288,496
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
Normal and Neoplastic Growth in the Brain
|
5P01CA096832-13
|
$2,039,886
|
BAKER, SUZANNE
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Tyrosine kinase inhibitors for the treatment of childhood AML
|
5R01CA138744-08
|
$343,388
|
BAKER, SHARYN
|
OHIO STATE UNIVERSITY
|
|
Interferon Activated Necroptosis as a New Therapeutic Avenue for Kidney Cancer
|
5R01CA168621-04
|
$379,725
|
BALACHANDRAN, SIDDHARTH
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
Dusp4 in breast cancer: tumor suppressor biology and therapeutic strategies
|
5R00CA181491-04
|
$250,586
|
BALKO, JUSTIN
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
SPORE: DF/HCC SPORE in GASTROINTESTINAL CANCER
|
5P50CA127003-10
|
$2,293,187
|
BASS, ADAM
|
DANA-FARBER CANCER INST
|
|
ARHI (DIRAS3) in Autophagy and Dormancy of Ovarian Cancer
|
3R01CA135354-07S1
|
$99,082
|
BAST, ROBERT
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
ARHI (DIRAS3) in Autophagy and Dormancy of Ovarian Cancer
|
5R01CA135354-07
|
$380,000
|
BAST, ROBERT
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
MD Anderson Cancer Center EDRN- CVC for Early Detection of Ovarian Cancer
|
5U01CA200462-02
|
$889,216
|
BAST, ROBERT
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Angiogenesis-targeting therapy for glioblastoma
|
3R01CA129371-10S1
|
$251,370
|
BATCHELOR, TRACY
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Training Program in Nervous System Tumors
|
5K12CA090354-17
|
$805,200
|
BATCHELOR, TRACY
|
MASSACHUSETTS GENERAL HOSPITAL
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|